Home›Trial›NCT05919511
NCT05919511RECRUITING

Observational Study for Patients at Risk for Chronic Graft-Versus-Host Disease

Study Summary

The purpose of this prospective observational study is to collect data from participants who have recently had an allogenic Stem Cell Transplant(alloSCT) and are at risk of Chronic Graft Versus Host Disease(cGVHD)

Conditions
cGVHD
Interventions / Drugs
Non-Interventional
View on ClinicalTrials.gov ↗
Sponsor
INCY
Incyte Corporation
Oncology
F35/100
Study Details
Enrollment1500 participants
Primary Completion—
Lead SponsorIncyte Corporation
Data Retrieved2026-04-11 02:55:29.647856+00:00
What This Trial Means for Biotech Investors
Trial Phase Context
Status & Expected Data

Currently recruiting: the trial is enrolling patients. A data readout is not expected until after enrollment closes and the follow-up period is complete.

Enrolled: 1,500 participants
Sponsor Catalyst Profile

Incyte Corporation (INCY) is the sponsoring company for this trial. BiotechSign currently grades this company F (35/100) based on composite catalyst signals across its full pipeline. This trial is one data point in that overall catalyst picture.

INCY Full Pipeline →All Companies →
Not financial advice. BiotechSign data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.